The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-line Docetaxel Chemotherapy for Metastatic Castration-resistant Prostate Cancer

Overview

Journal Clin Genitourin Cancer

Publisher Elsevier

Specialties Oncology
Urology

Date 2014 Jul 8

PMID 24999166

Citations 7

Authors

Jong Chul Park

Caroline F Pratz

Anteneh Tesfaye

Robert A Brodsky

Emmanuel S Antonarakis

Affiliations

Soon will be listed here.

Abstract

Background: Anticoagulants have been postulated to possess antitumor activity, although clinical data supporting this claim are conflicting. No definitive data exist on the clinical impact of anticoagulation therapy in patients with prostate cancer. The aim of this study was to investigate the association between therapeutic anticoagulant use and survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel chemotherapy.

Patients And Methods: We retrospectively reviewed the records of 247 consecutive patients with mCRPC who received first-line docetaxel chemotherapy between 1998 and 2010 at a single institution. Among them, 29 patients (11.7 %) received therapeutic anticoagulation (low-molecular-weight heparin [LMWH] or warfarin) for the treatment of venous thromboembolism. Univariate and multivariable Cox proportional hazards regression models were used to investigate the effect of anticoagulant use on overall survival.

Results: In univariate analysis, anticoagulant use was associated with improved survival (hazard ratio [HR], 0.61; P = .024). Median survival was 20.9 months in the anticoagulation group versus 17.1 months in the control group (P = .024). In multivariable analysis, anticoagulant use remained a significant predictor of survival after adjusting for other baseline prognostic factors (HR, 0.49; P = .023). When each anticoagulant was considered separately in the multivariable model, LMWH remained significantly prognostic for survival (HR, 0.48; P = .035), whereas warfarin use did not.

Conclusions: Anticoagulant use (LMWH in particular) is an independent predictor of improved survival in men with mCRPC receiving docetaxel. These data provide the impetus to further explore the antitumor properties of anticoagulants in patients with prostate cancer and warrant validation in prospective studies.

Citing Articles

The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.

Assayag J, Kim C, Chu H, Webster J Front Oncol. 2024; 13:1194718.

PMID: 38162494 PMC: 10757350. DOI: 10.3389/fonc.2023.1194718.

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Kahale L, Matar C, Hakoum M, Tsolakian I, Yosuico V, Terrenato I Cochrane Database Syst Rev. 2021; 12:CD006649.

PMID: 34878173 PMC: 8653422. DOI: 10.1002/14651858.CD006649.pub8.

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.

Kahale L, Matar C, Tsolakian I, Hakoum M, Yosuico V, Terrenato I Cochrane Database Syst Rev. 2021; 9:CD014739.

PMID: 34582035 PMC: 8477647. DOI: 10.1002/14651858.CD014739.

Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review.

Chen W, Kong D, Li L Asian J Androl. 2020; 23(2):163-169.

PMID: 33159024 PMC: 7991808. DOI: 10.4103/aja.aja_53_20.

Maintenance of stemness is associated with the interation of LRP6 and heparin-binding protein CCN2 autocrined by hepatocellular carcinoma.

Jia Q, Bu Y, Wang Z, Chen B, Zhang Q, Yu S J Exp Clin Cancer Res. 2017; 36(1):117.

PMID: 28870205 PMC: 5584530. DOI: 10.1186/s13046-017-0576-3.

References

Akl E, Kamath G, Kim S, Yosuico V, Barba M, Terrenato I . Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res. 2007; 26(2):175-84. View

Mousa S, Mohamed S . Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep. 2004; 12(4):683-8. View

Sorensen H, Mellemkjaer L, Olsen J, Baron J . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-50. DOI: 10.1056/NEJM200012213432504. View

Bobek V, Kovarik J . Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother. 2004; 58(4):213-9. DOI: 10.1016/j.biopha.2003.11.007. View

Chew H, Wun T, Harvey D, Zhou H, White R . Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4):458-64. DOI: 10.1001/archinte.166.4.458. View

Altinbas M, Coskun H, Er O, Ozkan M, Eser B, Unal A . A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2(8):1266-71. DOI: 10.1111/j.1538-7836.2004.00871.x. View

Gould M, Dembitzer A, Doyle R, Hastie T, Garber A . Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999; 130(10):800-9. DOI: 10.7326/0003-4819-130-10-199905180-00003. View

Klerk C, Smorenburg S, Otten H, Lensing A, Prins M, Piovella F . The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23(10):2130-5. DOI: 10.1200/JCO.2005.03.134. View

Dvorak H, Senger D, Dvorak A . Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 1983; 2(1):41-73. DOI: 10.1007/BF00046905. View

10.

Chew E, Wallace A . Demonstration of fibrin in early stages of experimental metastases. Cancer Res. 1976; 36(6):1904-9. View

11.

Collen A, Smorenburg S, Peters E, Lupu F, Koolwijk P, Van Noorden C . Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 2000; 60(21):6196-200. View

12.

Dvorak H, Nagy J, Berse B, Brown L, Yeo K, Yeo T . Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci. 1992; 667:101-11. DOI: 10.1111/j.1749-6632.1992.tb51603.x. View

13.

Lersch C, GERICKE D, Classen M . Efficacy of low-molecular-weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. An in vitro study and review of the literature. Urol Int. 1996; 56(4):230-3. DOI: 10.1159/000282848. View

14.

McCulloch P, George W . Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br J Cancer. 1989; 59(2):179-83. PMC: 2247008. DOI: 10.1038/bjc.1989.37. View

15.

Prandoni P, Piccioli A, Girolami A . Cancer and venous thromboembolism: an overview. Haematologica. 1999; 84(5):437-45. View

16.

Zacharski L, Henderson W, Rickles F, FORMAN W, Cornell Jr C, Forcier R . Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984; 53(10):2046-52. DOI: 10.1002/1097-0142(19840515)53:10<2046::aid-cncr2820531007>3.0.co;2-f. View

17.

Lebeau B, Chastang C, Brechot J, Capron F, Dautzenberg B, Delaisements C . Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer. 1994; 74(1):38-45. DOI: 10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e. View

18.

Prandoni P, Lensing A, Buller H, Carta M, Cogo A, Vigo M . Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339(8791):441-5. DOI: 10.1016/0140-6736(92)91054-c. View

19.

Dvorak H, Harvey V, Estrella P, Brown L, McDonagh J, Dvorak A . Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987; 57(6):673-86. View

20.

Simka M . Anti-metastatic activity of heparin is probably associated with modulation of SDF-1-CXCR4 axis. Med Hypotheses. 2007; 69(3):709. DOI: 10.1016/j.mehy.2007.01.008. View